Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
J Intensive Care Med ; 33(2): 128-133, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29141525

ABSTRACT

BACKGROUND: Acute heart failure (AHF) is one of the leading causes of admission to emergency department (ED); severe hypoxemic AHF may be treated with noninvasive ventilation (NIV). Despite the demonstrated clinical efficacy of NIV in relieving symptoms of AHF, less is known about the hyperacute effects of bilevel positive airway pressure (BiPAP) ventilation on hemodynamics of patients admitted to ED for AHF. We therefore aimed to assess the effect of BiPAP ventilation on principal hemodynamic, respiratory, pulse oximetry, and microcirculation indexes in patients admitted to ED for AHF, needing NIV. METHODS: Twenty consecutive patients admitted to ED for AHF and left ventricular systolic dysfunction, needing NIV, were enrolled in the study; all patients were treated with NIV in BiPAP mode. The following parameters were measured at admission to ED (T0, baseline before treatment), 3 hours after admission and initiation of BiPAP NIV (T1), and after 6 hours (T2): arterial blood oxygenation (pH, partial pressure of oxygen in the alveoli/fraction of inspired oxygen ratio, Paco2, lactate concentration, HCO3-), hemodynamics (tricuspid annular plane systolic excursion, transpulmonary gradient, transaortic gradient, inferior vena cava diameter, brain natriuretic peptide [BNP] levels), microcirculation perfusion (end-tidal CO2 [etco2], peripheral venous oxygen saturation [SpvO2]). RESULTS: All evaluated indexes significantly improved over time (analysis of variance, P < .001 in quite all cases.). CONCLUSIONS: The BiPAP NIV may rapidly ameliorate several hemodynamic, arterial blood gas, and microcirculation indexes in patients with AHF and left ventricular systolic dysfunction.


Subject(s)
Acidosis, Respiratory/therapy , Continuous Positive Airway Pressure/methods , Heart Failure, Systolic/therapy , Hemodynamics , Hypercapnia/therapy , Hypoxia/therapy , Respiratory Insufficiency/therapy , Ventricular Dysfunction, Left/therapy , Acidosis, Respiratory/blood , Acidosis, Respiratory/etiology , Acute Disease , Aged , Aged, 80 and over , Echocardiography , Emergency Service, Hospital , Female , Heart Failure, Systolic/blood , Heart Failure, Systolic/complications , Heart Failure, Systolic/diagnostic imaging , Humans , Hydrogen-Ion Concentration , Hypercapnia/blood , Hypercapnia/etiology , Hypoxia/blood , Hypoxia/etiology , Linear Models , Male , Microcirculation , Multivariate Analysis , Natriuretic Peptide, Brain/blood , Noninvasive Ventilation , Oximetry , Prospective Studies , Respiratory Insufficiency/blood , Respiratory Insufficiency/etiology , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/complications , Ventricular Dysfunction, Left/diagnostic imaging
3.
Autoimmun Rev ; 12(1): 60-5, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22884556

ABSTRACT

Idiopathic recurrent acute pericarditis (IRAP) represents the most troublesome complication of acute pericarditis and occurs in up to 20-50% of patients. It is generally idiopathic or postcardiac injury. IRAP is a disease of suspected immune-mediated pathogenesis. On the other hand, it has been suggested that some of these patients might have an atypical or subclinical form of an autoinflammatory disease, e.g. genetic disorders characterized by primary dysfunction of the innate immune system and caused by mutations of genes involved in the inflammatory response. We found that IRAP patients were negative for mutations associated with familial Mediterranean fever, but 6% (8/131 patients) carry a mutation in the TNFRSF1A gene, encoding the receptor for tumor necrosis factor-alfa. C-reactive protein (CRP) may be useful to follow the disease activity and guide the appropriate length of therapy, with continuation of the attack doses of the drugs until CRP normalization, at which time tapering may be considered. IRAP often needs a multidrug therapy: NSAIDs or aspirin at high dosages every 6-8h, corticosteroids only rarely, at low dosages and with a very gradual tapering (months) and colchicine at low dosages if tolerated. Anakinra could be a solution for patients who do not tolerate other therapies.


Subject(s)
Autoimmune Diseases/immunology , Inflammation/immunology , Pericarditis/drug therapy , Pericarditis/immunology , Autoimmune Diseases/genetics , Humans , Inflammation/genetics , Pericarditis/genetics , Pericarditis/pathology , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...